Table 3 Psychiatric medications at baseline for patients receiving IM ketamine therapy
Total N = 452 | N (%) of patients | Median (IQR) prescriptions per patient |
|---|---|---|
All psychiatric medications | 354 (78%) | 3 (2–5) |
Antidepressant | 294 (65%) | 2 (1–2) |
Stimulant | 142 (31%) | 1 (1–1) |
Benzodiazepine | 141 (31%) | 1 (1–1) |
Antipsychotic | 135 (30%) | 1 (1–1) |
Anticonvulsant | 89 (20%) | 1 (1–1) |
Sedative/hypnotic | 76 (17%) | 1 (1–1) |
Anticonvulsant/mood stabilizer | 57 (13%) | 1 (1–1) |
Azapirone | 36 (8%) | 1 (1–1) |
Mood stabilizer | 22 (5%) | 1 (1–1) |
Dopamine agonist | 17 (4%) | 1 (1–1) |
Tricyclic antidepressant | 9 (2%) | 1 (1–1) |
Alcohol antagonist | 5 (1%) | 1 (1–1) |
Cannabis/cannabinoid | 4 (1%) | 1 (1–1) |
NMDA receptor antagonist | 2 (0.4%) | 1 (1–1) |
Opioid antagonist | 2 (0.4%) | 1 (1–1) |